OVERVIEW

Stock Information

Dec 17, 2018 4:38 PM EST
Copyright Nasdaq. Minimum 15 minutes delayed.

Press Releases

Nov 21, 2018

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 09, 2018

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Nov 07, 2018

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results

Oct 10, 2018

CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

Upcoming Events & Recent Presentations

There are currently no events scheduled.

Dec 2018

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Dec 2018

CRISPR Therapeutics Corporate Presentation

Nov 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

May 2018

2018 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Poster: Allogeneic CAR-T Cells with Multiple Therapeutically Favorable Edits Can Be Created Efficiently Using CRISPR/Cas9

Apr 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells

Apr 2018

2018 American Association for Cancer Research (AACR) Annual Meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen